NCT00238485View on ClinicalTrials.gov

An Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine 750-2000 mg/d in the Treatment of Manic Episodes of Bipolar I Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Bipolar I Disorder
Interventions
DRUG

Licarbazepine

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY